NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2
News release
by
NanoViricides
Vancouver
|
June 29, 2023 03:00 PM Eastern Daylight Time
NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.
Diwan told Proactive the Phase 1a/1b safety and efficacy clinical trial began June 17th and is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. The trial will use patients with mild to moderate COVID-19 to assess indication of efficacy.
Contact Details
Proactive Investors
+1 604-688-8158
